Ophthalmology · Juvenile Open-Angle Glaucoma

The 'Cellular Logjam': The Genetics of JOAG

At a Glance

Juvenile Open-Angle Glaucoma (JOAG) is frequently caused by a mutation in the MYOC gene. This mutation creates misfolded proteins that clog and destroy the eye's drainage cells, leading to high eye pressure. Genetic testing is highly recommended for families to guide treatment and protect vision.

Understanding the “why” behind a diagnosis can be empowering. In many cases of Juvenile Open-Angle Glaucoma (JOAG), the cause is written in the patient’s DNA. While several genes can be involved, the most common and well-studied is the MYOC gene, which provides instructions for making a protein called myocilin ^[1]^[2].

When this gene has a mutation, it doesn’t just stop working—it creates a microscopic complication within the eye’s drainage system that leads to high pressure.

The ‘Cellular Logjam’: How MYOC Causes JOAG

To understand how a tiny genetic change causes high eye pressure, it helps to look at the “trash collection” system of the eye’s drainage cells (trabecular meshwork):

Protein Misfolding: In a healthy eye, myocilin protein is folded into a specific shape and sent out of the cell. In JOAG, the mutated myocilin is “misfolded”—it has the wrong shape ^[3]^[4].
The Endoplasmic Reticulum (ER) Clog: Because it is the wrong shape, the protein gets stuck inside a part of the cell called the Endoplasmic Reticulum (ER), which acts like the cell’s factory and shipping center. It cannot be exported, so it begins to pile up ^[3]^[5].
ER Stress: This pile-up creates a “cellular logjam” known as ER stress. The cell recognizes something is wrong and activates the Unfolded Protein Response (UPR) to try and clear the mess ^[6]^[3].
Cell Death and Blockage: If the stress is constant (chronic), the UPR eventually fails. The cell becomes overwhelmed and dies (apoptosis). As these critical drainage cells die off, the eye’s “drain” becomes physically blocked, causing the fluid pressure (IOP) to skyrocket ^[6]^[7]^[8].

Other Genetic Players

While MYOC is the most frequent cause, other genes can also play a role:

CYP1B1: Often associated with younger onset or more severe cases, this gene is involved in the development of the eye’s drainage structures ^[9]^[10].
LTBP2 and OPTN: These are rarer causes but can lead to similar patterns of high pressure and nerve damage ^[11]^[12].

Why Genetic Testing and Counseling Matter

Current clinical guidelines strongly recommend genetic testing for JOAG patients and their families ^[13]^[14]. This is not just for information—it has practical benefits:

Early Detection for Family Members: Because JOAG is often autosomal dominant (meaning a child has a 50% chance of inheriting the mutation from an affected parent), testing can identify at-risk relatives before they lose any vision ^[15]^[1].
Surgical Success: Research shows that patients with MYOC mutations often have excellent results with “angle-based” surgeries like GATT, which specifically target the area where the cellular logjam is happening ^[15]^[16].
Future Therapies (With an Important Caveat): While scientists are currently researching gene-editing tools (like CRISPR) designed specifically to clear these misfolded proteins and stop the ER stress, these therapies are strictly in early laboratory stages and are not currently available ^[3]^[4]^[17]. They should not be relied upon to delay standard surgical treatments that can protect vision today.

Genetic counseling is a vital part of this process. A counselor can help you navigate the emotional and practical aspects of testing, explaining how the results might affect your family’s future and ensuring you have access to the most advanced care ^[13].

Common questions in this guide

How does the MYOC gene mutation cause juvenile glaucoma?

The MYOC gene mutation causes the eye to produce misfolded myocilin proteins. These abnormal proteins get stuck inside the eye's drainage cells, eventually causing the cells to die and physically block the fluid drain, which leads to high pressure.

Should my family get genetic testing for JOAG?

Yes, clinical guidelines strongly recommend genetic testing for JOAG patients and their families. Because the condition is often inherited, testing can identify at-risk relatives so they can be monitored and treated before experiencing any vision loss.

Does having a MYOC gene mutation change my JOAG treatment options?

Yes, knowing you have a MYOC mutation can guide surgical decisions. Patients with this specific mutation often have excellent outcomes with angle-based surgeries like GATT, which directly target the area of the eye where the drainage blockage occurs.

What are the chances of passing JOAG to my children?

Because JOAG linked to MYOC mutations is typically autosomal dominant, a child has a 50 percent chance of inheriting the gene mutation from an affected parent. A genetic counselor can help clarify your specific family risks.

Curated prompts to bring to your next appointment.

1.Is this case of JOAG caused by a mutation in the MYOC gene, and how does that affect our treatment plan?
2.If we find a specific mutation, which other family members (siblings, parents, cousins) should be tested?
3.Does a positive MYOC test mean angle-based surgeries like GATT are more likely to succeed?
4.Can you refer us to a genetic counselor who specializes in ophthalmic or pediatric conditions?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (17)

1
Prevalence of Myocilin Mutations in a Cohort of Patients with Juvenile Open-Angle Glaucoma from sub-Saharan Africa.
Olawoye O, Young BP, Nyunt AW, et al.
Ophthalmology. Glaucoma 2025; (8(5)):450-456 doi:10.1016/j.ogla.2025.04.010.
PMID: 40280414
2
The mutational spectrum of Myocilin gene among familial versus sporadic cases of Juvenile onset open angle glaucoma.
Gupta V, Somarajan BI, Gupta S, et al.
Eye (London, England) 2021; (35(2)):400-408 doi:10.1038/s41433-020-0850-z.
PMID: 32300215
3
Therapeutic mRNA delivery of CRISPR-Cas9 to the trabecular meshwork reverses ocular hypertension in myocilin glaucoma.
Yacoub S, Kaipa BR, Li L, et al.
Molecular therapy. Methods & clinical development 2025; (33(4)):101614 doi:10.1016/j.omtm.2025.101614.
PMID: 41210166
4
Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucoma.
Patil SV, Kaipa BR, Ranshing S, et al.
Research square 2023; doi:10.21203/rs.3.rs-3740880/v1.
PMID: 38196579
5
Myocilin misfolding and glaucoma: A 20-year update.
Saccuzzo EG, Youngblood HA, Lieberman RL
Progress in retinal and eye research 2023; (95()):101188 doi:10.1016/j.preteyeres.2023.101188.
PMID: 37217093
6
Histochemical Analysis of Glaucoma Caused by a Myocilin Mutation in a Human Donor Eye.
van der Heide CJ, Alward WLM, Flamme-Wiese M, et al.
Ophthalmology. Glaucoma 2018; (1(2)):132-138 doi:10.1016/j.ogla.2018.08.004.
PMID: 30906929
7
Myocilin Gene Mutation Induced Autophagy Activation Causes Dysfunction of Trabecular Meshwork Cells.
Yan X, Wu S, Liu Q, et al.
Frontiers in cell and developmental biology 2022; (10()):900777 doi:10.3389/fcell.2022.900777.
PMID: 35615698
8
Expression of Mutant Myocilin Induces Abnormal Intracellular Accumulation of Selected Extracellular Matrix Proteins in the Trabecular Meshwork.
Kasetti RB, Phan TN, Millar JC, Zode GS
Investigative ophthalmology & visual science 2016; (57(14)):6058-6069 doi:10.1167/iovs.16-19610.
PMID: 27820874
9
Identification and structural analysis of pathogenic variants in MYOC and CYP1B1 genes in Indian JOAG patients.
Yadav M, Kumar M, Dhull CS, et al.
Japanese journal of ophthalmology 2025; (69(3)):469-481 doi:10.1007/s10384-025-01173-8.
PMID: 39998747
10
A rare optineurin mutation in an Indian family with coexistence of JOAG and PCG.
Yadav M, Yadav A, Bhardwaj A, et al.
Indian journal of ophthalmology 2023; (71(8)):3016-3023 doi:10.4103/IJO.IJO_3383_22.
PMID: 37530275
11
A novel LTBP2 gene variant in a Turkish family with juvenile-onset open-angle glaucoma.
Bozkurt B, Bağcı O, Üzüm S, Çora T
Ophthalmic genetics 2024; (45(4)):384-389 doi:10.1080/13816810.2024.2331540.
PMID: 38557215
12
Paucity of optineurin gene variants in Indian juvenile open-angle glaucoma patients.
Yadav M, Dhull CS, Sachdeva S, et al.
Indian journal of ophthalmology 2025; (73(8)):1181-1189 doi:10.4103/IJO.IJO_1512_24.
PMID: 40719721
13
Glaucoma Genetics: Lessons Learned and the New Frontier.
Wiggs JL, Pasquale LR
Ophthalmology. Glaucoma 2025; (8(5S)):S27-S32 doi:10.1016/j.ogla.2025.07.009.
PMID: 40905900
14
A recurrent G367R mutation in MYOC associated with juvenile open angle glaucoma in a large Chinese family.
Yao YH, Wang YQ, Fang WF, et al.
International journal of ophthalmology 2018; (11(3)):369-374 doi:10.18240/ijo.2018.03.04.
PMID: 29600168
15
Gonioscopy-Assisted Transluminal Trabeculotomy for Myocilin-Associated Juvenile Open-Angle Glaucoma: A Case Series of 8 Eyes Over 2.2 to 4.1 Years.
Boese EA, Alward WLM, Fingert JH
Ophthalmology. Glaucoma 2025; (8(5)):466-473 doi:10.1016/j.ogla.2025.03.011.
PMID: 40188877
16
Gonioscopy-Assisted Transluminal Trabeculotomy for Myocilin Juvenile Glaucoma.
Boese EA, Alward WLM, Fingert JH
Ophthalmology. Glaucoma 2022; (5(3)):369-370 doi:10.1016/j.ogla.2021.07.003.
PMID: 34273563
17
AAV-DJ-Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma.
Wan Y, Liu X, Yan X, et al.
Investigative ophthalmology & visual science 2026; (67(1)):48 doi:10.1167/iovs.67.1.48.
PMID: 41569028

This page explains the genetics of JOAG for educational purposes only and does not constitute medical advice. Always consult a pediatric ophthalmologist or genetic counselor regarding genetic testing and treatment options.

Get notified when new evidence is published on Juvenile glaucoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents